Ultiva Pdr/Conc/Soln for Infus 1mg/vial Malta - angličtina - Medicines Authority

ultiva pdr/conc/soln for infus 1mg/vial

aspen pharma trading limited 3016 lake drive city west businees campus dublin 24, ireland - remifentanil hydrochloride - powder for concentrate for solution for infusion - remifentanil hydrochloride 1 mg - anesthetics

Ipol Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

ipol

pharmacy retailing (nz) ltd t/a healthcare logistics - polio virus type 1 29 dagu (mahoney by parallel line method (equiv to 40 dagu by sigmoid method)); polio virus type 2 7 dagu (mef1 by parallel line method (equiv to 8 dagu by sigmoid method)); polio virus type 3 26 dagu (saukett by parallel line method (equiv to 32 dagu by sigmoid method)) - suspension for injection - active: polio virus type 1 29 dagu (mahoney by parallel line method (equiv to 40 dagu by sigmoid method)) polio virus type 2 7 dagu (mef1 by parallel line method (equiv to 8 dagu by sigmoid method)) polio virus type 3 26 dagu (saukett by parallel line method (equiv to 32 dagu by sigmoid method)) excipient: formaldehyde phenoxyethanol polysorbate 80 water for injection - ipol is indicated for active immunisation of infants, children and adults for the prevention of poliomyelitis. recommendations for the use of live and inactivated poliovirus vaccines are described in the national immunisation guidelines. 1. general recommendations. it is recommended that all infants, unimmunised children and adolescents not previously immunised be vaccinated routinely against paralytic poliomyelitis. ipol should be offered to patients who have refused opv, or in whom opv is contraindicated. 2. ipol is also indicated for: · the primary vaccination of immunocompromised individuals of all ages (see precautions), and household contacts of such individuals (when vaccination is indicated) · unvaccinated or inadequately vaccinated (*) adults, particularly if at increased risk of exposure to live poliovirus, including: · travellers to areas or countries where poliomyelitis is epidemic or endemic; · laboratory workers handling specimens which may contain polioviruses; · health care workers in close contact with patients who may be excreting polioviruses. (*) such as those who had not completed a primary series of vaccination or not received a booster dose since infancy.

ULTIVA POWDER FOR SOLUTION Kanada - angličtina - Health Canada

ultiva powder for solution

abbvie corporation - remifentanil (remifentanil hydrochloride) - powder for solution - 1mg - remifentanil (remifentanil hydrochloride) 1mg - opiate agonists

ULTIVA POWDER FOR SOLUTION Kanada - angličtina - Health Canada

ultiva powder for solution

abbvie corporation - remifentanil (remifentanil hydrochloride) - powder for solution - 2mg - remifentanil (remifentanil hydrochloride) 2mg - opiate agonists

ULTIVA POWDER FOR SOLUTION Kanada - angličtina - Health Canada

ultiva powder for solution

abbvie corporation - remifentanil (remifentanil hydrochloride) - powder for solution - 5mg - remifentanil (remifentanil hydrochloride) 5mg - opiate agonists

CULTIVATED RYE- secale cereale solution
CULTIVATED WHEAT- triticum aestivum solution
MUSTARD- brassica spp. solution
RED CLOV Spojené štáty - angličtina - NLM (National Library of Medicine)

cultivated rye- secale cereale solution cultivated wheat- triticum aestivum solution mustard- brassica spp. solution red clov

greer laboratories, inc. - secale cereale pollen (unii: i6kaz8ao1o) (secale cereale pollen - unii:i6kaz8ao1o) - non-standardized allergenic extracts are indicated for: - skin test diagnosis of patients with a clinical history of allergies to one or more of the specific non-standardized allergens. - immunotherapy for the reduction of allergen-induced allergic symptoms confirmed by appropriate positive skin tests or by in vitro testing for allergen-specific ige antibodies. food extracts have not been proven safe or effective in allergen immunotherapy. non-standardized allergenic extracts are contraindicated in patients with: - severe, unstable or uncontrolled asthma - history of any severe systemic or local allergic reaction to an allergen extract 8.1 pregnancy risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. there are no human or animal data to establish the presence or absence of non-standardize